Sorfequiline is an investigational new drug that is being evaluated by Global Alliance for TB Drug Development for the treatment of tuberculosis. It is an adenosine triphosphatase inhibitor. Sorfequiline is a next generation diarylquinoline mycobacterial ATP synthase inhibitor. Compared to bedaquiline, it is claimed to have greater potency and reduced cardiac QT prolongation.
Clinical trials It is currently in phase 2 clinical trials.
References


